CBG166

CBG166 is an investigational autologous CAR-T cell therapy targeting **glypican-3 (GPC3)**, currently being evaluated in a phase I clinical trial for advanced hepatocellular carcinoma (liver cancer) that cannot be surgically removed and is refractory to prior standard treatments. The therapy involves engineering a patient's own T cells to express a chimeric antigen receptor (CAR) directed against GPC3—a protein highly expressed on hepatocellular carcinoma cells. By redirecting the immune response toward GPC3+ tumor cells, CBG166 aims to enhance anti-tumor activity. The trial is being sponsored and developed by Zhejiang University in China, with recruitment as of mid-2025. No additional public information about broader indications, commercial formulations, or alternate names is currently available[1][8].

Other names

anti-GPC3 CAR-Tanti-GPC-3 CAR-Tanti-GPC 3 CAR-TCAR-GPC3 T CellsCAR-GPC-3 T CellsCAR-GPC 3 T Cellsautologous GPC3 CAR-T cells